Q&A with Miguel Regueiro: Hot Topics in IBD

Miguel Regueiro, MD, University of Pittsburgh Medical Center, highlighted the hot topics in IBD at the 2015 Advances in Inflammatory Bowel Diseases.

Accordig to Regueiro, "Biosimilars and inflammatory bowel disease are really emerging from a cost perspective, and there will probably be two from the biologic domain from the inflammatory bowel disease in the next couple of years. One will be similar to adalimumab and and one will be similar to infliximab. So I think cost will make sense, the question is are they interchangeable and where do they position within that domain?"